LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Avidity Biosciences Inc

Suletud

SektorTervishoid

30.37 4.76

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

28.63

Max

30.39

Põhinäitajad

By Trading Economics

Sissetulek

-14M

-116M

Müük

-1.4M

1.6M

Aktsiakasum

-0.8

Kasumimarginaal

-7,360.013

Töötajad

391

EBITDA

-23M

-120M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+137.68% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-356M

3.5B

Eelmine avamishind

25.61

Eelmine sulgemishind

30.37

Uudiste sentiment

By Acuity

23%

77%

43 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Avidity Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 09:30 UTC

Peamised uudised

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Avidity Biosciences Inc Prognoos

Hinnasiht

By TipRanks

137.68% tõus

12 kuu keskmine prognoos

Keskmine 67.5 USD  137.68%

Kõrge 96 USD

Madal 48 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Avidity Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

12

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

25.575 / 32.65Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Neutral Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

43 / 382 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.